Aortic Stenosis From the Perspective of the Current Guidelines by Marko Mornar Jelavić & Hrvoje Pintarić
RAD CASA - Medical Sciences   -   www.rad-med.com July 2019   -   Vol 537 = 46-4737
Aortic Stenosis From the Perspective 
of  the Current Guidelines
Marko Mornar Jelavic1,2       , Hrvoje Pintaric2,3
1 Institute for Cardiovascular Prevention and Rehabilitation, Zagreb, Croatia
2 School of Dental Medicine, University of Zagreb, Zagreb, Croatia
3 Department of Emergency Medicine, Clinic for Internal Medicine, University Hospital Center “Sestre milosrdnice”, Zagreb, 
Croatia
AbstrAct:
Aortic stenosis (AS) is one of the most common valvular diseases encountered in clinical practice. It is 
most frequently caused by degenerative aortic valve fibrosis and calcification, and in a lesser number 
of cases by the calcification of congenital deformed aortic valve (bicuspid); it may occasionally develop 
after rheumatic fever. 
Valve fibrosis and calcification lead to progressive valve restriction, obstruction and increased afterload 
with left ventricle remodelling for normalization of wall tension and cardiac output. During time, such 
hypertrophic and fibrotic myocardium deteriorates, resulting in heart failure. Generally, current guide-
lines of the European Society of Cardiology (ESC) recommend aortic valve replacement (AVR) when 
the aortic valve is severely stenotic and the patient is symptomatic. Most asymptomatic patients with 
severe AS should be managed conservatively, except for those with systolic LV dysfunction, an abnormal 
exercise test, very severe aortic stenosis, severe valve calcification, markedly elevated cardiac biomarkers, 
and severe pulmonary hypertension without other explanation.
This article will review our current understanding of the pathophysiology of AS and provide detailed 
information about clinical presentation, diagnostic procedures, disease course, and different treatment 
strategies for various groups of these patients. 
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Sažetak:
Stenoza aorte (AS) jedna je od najčešćih bolesti srčanih valvulau kliničkoj praksi. Najčešće je uzroko-
vana degenerativnom fibrozom aortnih zalistaka i kalcifikacijom, dok su rjeđi razlozi kongenitalno 
deformirane zalisci aorte (bikuspidalni) ili posljedice reumatske groznice.
Fibroza i kalcifikacija valvula dovode do progresivnog ograničenja, opstrukcije i povećanog after-loa-
da koje dovodi do remodeliranja lijeve klijetke kako bi se kompenzirala napetost zida i ejekcijska 
frakcija. Tijekom tog vremena, takav hipertrofični i fibrotični miokardij se pogoršava, što dovodi 
do zatajenja srca. Općenito, sadašnje smjernice Europskog kardiološkog društva (ESC) ukazuju na 
zamjenu aortnih valvula (AVR) kada je ona ozbiljno stenotična i pacijent je simptomatičan. Većini 
asimptomatskih bolesnika s teškom AS treba upravljati konzervativno, osim onih s disfunkcijom 
sistolne LV, abnormalnim testom napora, teškom aortnom stenozom, teškom kalcifikacijom valvula, 
izrazito povišenim srčanim biomarkerima i teškom plućnom hipertenzijom bez daljnjeg objašnjenja.
Ovaj članak će se prikazati pregled  i naše sadašnje razumijevanje patofiziologije AS-a i te će pružiti 
detaljne informacije o kliničkoj slici, dijagnostičkim postupcima, tijeku bolesti i različitim strategija-
ma liječenja za različite skupine bolesnika sa aortnom stenozom.
ključne riječi: aortna stenoza, zamjena aortnih zalistaka, transkatetersna implantacija valvula
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introduction
Calcific aortic stenosis (AS) is present at around 2%  and 12% 
of patients aged ≥65 and ≥75 years, respectively (1-6). In the last 
group, severe aortic stenosis is present at 3.4% of patients. With 
the aging of the population, the number of individuals with AS 
is expected to increase twofold to threefold in developed coun-
tries in the coming decades1-6.
Valvular AS may be a consequence of superimposed calcification 
of congenital bicuspid valve, normal trileaflet valve and rheumat-
ic diseased valve. Also, it is important to evaluate possible ob-
struction of left ventricular (LV) outflow which may occur above 
the valve (supravalvular stenosis) or below the valve (discrete 
subvalvular stenosis). Finally, hypertrophic cardiomyopathy may 
cause subaortic obstruction1,2. 
Calcific (formerly “senile” or “degenerative”) aortic valve disease, 
affecting a congenital bicuspid or normal trileaflet valve, is now 
the most common cause of AS in adults1,2. It may be a conse-
quence of normal degenerative process as well as due to influence 
of atherosclerotic promoting factors, i.e. dyslipidemia, hyper-
glycemia, arterial hypertension, smoking, obesity, etc1-11. It is 
important to emphasize that aortic sclerosis, even in the absence 
of valve obstruction or known cardiovascular disease, is associ-
ated with an increased risk of myocardial infarction (MI) and 
cardiovascular and all-cause mortality2,5. 
PathoPhySiology of aortic StenoSiS 
Due to chronic valve obstruction and increased afterload, the 
ventricle typically undergoes hypertrophic remodeling (concen-
tric remodeling, concentric hypertrophy, or eccentric hyper-
trophy) characterized by myocyte hypertrophy and increased 
wall thickness. It reduces wall stress (afterload) and maintains 
LV ejection performance. But, increased or maladaptive (in-
sufficient) LV remodeling may be associated with more severe 
ventricular dysfunction and heart failure (HF) symptoms, as well 
as higher mortality13-15. 
Hypertrophic remodeling also impairs diastolic myocardial relax-
ation and increases stiffness16,17, as modulated by cardiovascular 
and metabolic comorbidities18. Higher cardiomyocyte stiffness, 
increased myocardial fibrosis as a part of hypertrophic remod-
eling process, advanced-glycation end products, and metabolic 
abnormalities each contribute to increased chamber stiffness and 
higher end-diastolic pressures16. Increased chamber pressures, 
especially during diastole, leads to pulmonary hypertension 
in many patients with AS. The hypertrophied left ventricle, 
increased systolic pressure and prolongation of ejection increases 
myocardial oxygen consumption. Patients with AS may have 
normal epicardial coronary arteries, but decreased myocardial 
capillary density in the hypertrophied ventricle, increased LV 
end-diastolic pressure, and a shortened diastole decreases the 
coronary perfusion pressure gradient and myocardial blood flow. 
It creates an imbalance between myocardial oxygen supply and 
demand, especially in the subendocardium1,2,16-18.
clinical PreSentation
Most patients presents with systolic murmur on physical exam-
ination, with confirmation of the diagnosis by echocardiography. 
The most common clinical presentation is a gradual decrease 
in exercise tolerance, fatigue, or dyspnea on exertion, due to 
LV diastolic dysfunction, elevated end-diastolic pressure and 
pulmonary congestion1,2,19,20. Also, exertional symptoms may be 
a consequence of the limited ability to increase cardiac output 
with exercise. More severe exertional dyspnea, with orthopnea, 
paroxysmal nocturnal dyspnea, and pulmonary edema, reflects 
various degrees of pulmonary venous hypertension1,2. 
Angina during exertion is a frequent symptom, caused with im-
balance of increased oxygen needs in hypertrophied myocardium 
and decreased delivery secondary to the excessive compression 
of coronary vessels. Syncope most often is caused by inadequate 
increase in cardiac output related to valvular stenosis, systemic 




The specific finding with severe AS is a slow-rising, late-peaking 
and low-amplitude carotid impulse (parvus and tardus)2. The 
ejection systolic murmur of AS typically is heard best at the base 
of the heart and radiation to the neck. It may become softer with 
failing ventricle. Splitting of second heart sound (S2) implies the 
aortic valve leaflets are flexible enough for creating an audible 
closing sound (A2). The intensity of the systolic murmur varies 
according to the duration of diastole (atrial fibrillation, prema-
ture beats). It is augmented by squatting, which increases stroke 
volume, and reduced during the strain of the Valsalva maneuver 
and standing due to the reduction of transvalvular flow2.
Diagnostic testing
Echocardiography It is the standard approach for evaluating and 
following patients with AS and selecting them for operation. 
According to the guidelines1,2,21, valve obstruction to LV outflow 
is graded as: 
1) mild obstruction: aortic jet velocity of 2.0 - 2.9 m/sec, mean 
gradient ≤20 mm Hg, aortic valve area (AVA) 1.5 - 2.0 cm2;
2) moderate obstruction: aortic jet velocity of 3.0 - 3.9 m/sec, 
mean gradient 20 - 39 mm Hg, AVA 1.0 - 1.5 cm2; and 
3) severe obstruction: aortic jet velocity of ≥4 m/sec, mean gradi-
ent ≥40 mm Hg, AVA ≤1.0 cm2. 
Furthermore, four categories of aortic stenosis can be de-
fined1,2,21:
a) High-gradient AS (valve area <1.0 cm2, mean gradient 
>40mmHg). Severe aortic stenosis can be assumed irrespective of 
whether LVEF and flow are normal or reduced.
b) Low-flow, low-gradient AS with reduced ejection frac-
tion [valve area <1.0 cm2, mean gradient <40mmHg, ejection 
fraction <50%, stroke volume index (SVi) <35mL/m2]. There is 
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LV dysfunction with reduced blood flow (SVI <35mL/m2). In 
this situation, dobutamine stress echocardiography (DSE) can 
help to distinguish between pseudo-severe and true severe AS. 
More precisely, DSE may allow iden-tification of the presence 
or absence of contractile reserve (flow reserve), which is de-
fined as an increase in stroke volume ≥20% on dobutamine. In 
the absence of contractile reserve, no solid conclusions can be 
drawn with regard to severity of AS. In contrast, in the pres-
ence of a contractile reserve, differential diag¬nosis between 
true severe and pseudo-severe AS (reduced valve opening due 
to primary myocardial disease and limited contractile driving 
forces) may be possible. In true severe AS, a significant increase 
in transaortic gradients with increasing flow is observed whereas 
the calculated valve area remains small (e.g. mean gradient >40 
mmHg and AVA < 1.0–1.2 cm2 at peak stress). In pseudo-severe 
AS, gradients typically remain low, while the calculated valve 
area increases (e.g. mean gradient < 30–40 mmHg and AVA > 
1.0–1.2 cm2 at peak stress).
c) Low-flow, low-gradient AS with preserved ejection fraction 
[valve area <1.0 cm2, mean gradient <40mmHg, ejection frac-
tion >50%, SVi <35mL/m2]. This is typically encountered in 
the elderly and is associated with small ventricular size, marked 
LV hypertrophy and frequently a history of hypertension.
The diagnosis of severe aortic stenosis in this setting remains 
challenging and includes positive clinical criteria (typical symp-
toms without other explanation, elderly patient (>70 years)), 
qualitative imaging data (LV hypertrophy and reduced LV lon-
gitudinal function without other explanation) and quantitative 
imaging data (mean gradient 30-40 mmHg, AVA ≤ 0.8 cm2, low 
flow (SVI <35 mL/m2). Finally, the degree of valve calcification 
by MSCT is related to aortic stenosis severity and outcome. Its 
assessment has therefore gained increasing importance in this 
setting.
d) Normal-flow, low-gradient AS with preserved ejection frac-
tion [valve area <1.0 cm2, mean gradient <40mmHg, ejection 
fraction ≥50%, SVi >35mL/m2]. These patients will in general 
have only moderate aortic stenosis. 
Finally, valve area may be ≥1.0 cm2 with a peak velocity higher 
than 4 m/s and mean gradient ≥40 mmHg in the pres¬ence of 
a high transvalvular flow. This may be due to concomitant AR 
or shunt lesions. Although valve area may not indicate severe 
AS, haemodynamics remain consistent with severe LV pressure 
overload and therefore severe aortic valve disease. For clinical 
decision-making, reversible causes of increased flow in case of 
high cardiac output (fever, anaemia, hyperthyroidism, etc.) must 
be excluded.
Exercise stress testing. It may be used in apparently asymp-
tomatic patients to unmask symptoms or demonstrate limited 
exercise capacity or an abnormal blood pressure response1,2. It 
should be absolutely avoided in symptomatic patients.
Computed tomography (CT). It may be used in cases with sus-
pected aortic root disease, especially at patients with a bicuspid 
valve. Evaluation of aortic dimensions at several levels is neces-
sary for clinical decision making and surgical planning. Also, 
CT may be helpful when the severity of the stenosis is in doubt, 
particularly in those with low-flow, low-gradient AS1,2.
Cardiac catheterization. It is now recommended only when 
noninvasive tests are inconclusive, when clinical and echocardio-
graphic findings are discrepant, and for coronary angiography 
before surgical intervention1,2. 
Cardiac magnetic resonance (CMR). It is useful for evaluation 
of LV volume, function, and mass1,2. CMR is used in assessing 
aortic dimensions in patients with a bicuspid valve. It is also 
practical for assesing myocardial fibrosis and can be used instead 
of CT for evaluation of valve morphology, vascular anatomy, 
and annular dimensions in preparation for transcatheter aortic 




The rate of progression of AS is highly variable and difficult to 
predict. The factors associated with more rapid hemodynamic 
progression included older age, more severe leaflet calcification, 
renal insufficiency, hypertension, obesity, metabolic syndrome, 
smoking and hyperlipidemia1,2,6,8,9.
Asymptomatic patients with moderate to severe AS have 
excellent prognosis1,2,22. Several predictors of symptoms onset 
at patients with asymptomatic severe AS are abnormal exercise 
test, elevated BNP, moderate to severe valve calcification, very 
high aortic velocity (>5 or 5.5 m/sec), rapid increase in aortic 
velocity, increased hypertrophic LV remodeling, reduced LV 
longitudinal systolic strain, myocardial fibrosis and pulmonary 
hypertension. The strongest predictor of progression to symp-
toms is the Doppler aortic jet velocity1,2,19,21,23,24. 
Exercise testing monitored by a physician should be applied 
in adults with severe AS when symptom status is unclear, and 
patients who develop symptoms or exhibit a decrease in blood 
pressure with exertion should be considered to have symptomat-
ic disease. An elevated BNP level may be helpful when symp-
toms are equivocal or when stenosis severity is only moderate, 
but the role of BNP monitoring in the evaluation of disease 
progression has not been fully defined1,2.
Generally, repeat echocardiographic imaging is performed every 
6 to 12 months for severe AS, every 1 to 2 years for moderate 
AS, and every 3 to 5 years for mild AS, unless a change in signs 
or symptoms prompts repeat imaging sooner1,2.
Symptomatic patients
Once even mild symptoms are present, survival is poor unless 
outflow obstruction is relieved. The average survival with-
out aortic valve replacement (AVR) is only 1 to 3 years after 
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symptom onset1,2,25-28. Also, the outlook is poorest when the 
left ventricle has failed and the cardiac output and transvalvular 
gradient are both low. The risk of sudden death is high with 
symptomatic severe AS, so these patients should be promptly re-
ferred for AVR. In patients who do not undergo AVR, recurrent 
hospitalizations for angina and decompensated heart failure are 
common, associated with significant consumption of health care 
resources 1,2,25-28.
treatment
Studies revealed that medical treatment has no influence on 
disease progression and aortic valve replacement (AVR) is supe-
rior to medical therapy at patients with severe symptomatic AS 
1,2,29-61. It is of mutual importance that patients report promptly 
the development of any symptoms possibly related to AS as the 
risk of sudden death increases dramatically once symptoms are 
present. In asymptomatic patients with AS of any degree, evalu-
ation and treatment for conventional cardiovascular risk factors 
is recommended in accordance with established guidelines. 
Hypertension treatment reduces ventricular afterload and 
hypetrophic LV remodeling. Also, vasodilation is accompanied 
by increases in stroke volume, even in patients with severe AS1,2. 
Because the renin-angiotensin system is upregulated in the valve 
and ventricle of patients with AS, angiotensin-converting-en-
zyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) 
may preferentially considered1,2.
Coronary artery disease and statin prescribtion should be guided 
according to the primary and secondary preventio guidelines 
and not be infleunced by the presence of AS1,2.
Atrial fibrillation (AF) or atrial flutter are frequent at patients 
with AS, especially with concomitatnt mitral valve disease. As 
the loss of the left atrial „buster pump“ during AF affects LV 
filling and may cause sudden fall in cardiac output and serious 
hypotension, clinicans must choose between the two treatment 
strategies, rate and rhytm control. In patients with chronic 
stable HF diuretics may reduce congestion and provide some 
symptomatic relief prior to valve replacement. Patients with 
acute decompensated HF may benefit from medical therapy as 
a bridge to definitive therapy with valve replacement. Nitro-
prusside has been used during hemodynamic monitoring in the 
intensive care unit to unload the left heart, reduce congestion, 
and improve forward flow. Similarly, phosphodiesterase type 5 
inhibition has been shown to provide acute improvements in 
pulmonary and systemic hemodynamics resulting in biventric-
ular unloading 1,2. These medications may improve the patient’s 
hemodynamic status, allowing the AVR procedure to be per-
formed more safely.
Symptomatic severe aortic stenosis 
Intervention is indicated1,2 in symptomatic patients with severe, 
high-gradient aortic stenosis (mean gradient  ≥40 mmHg or 
peak velocity ≥4.0 m/s) (Class I, Level B). 
Intervention is indicated in symptomatic patients with severe 
low-flow, low-gradient (<40 mmHg) aortic stenosis with re-
duced ejection fraction and evidence of flow (contractile) reserve 
excluding pseudosevere aortic stenosis (Class I, Level C).
Intervention should be considered in symptomatic patients with 
low-flow, low-gradient (<40 mmHg) aortic stenosis with normal 
ejection fraction after careful confirmation of severe aortic ste-
nosis (Class IIa, Level C). 
Intervention should be considered in symptomatic patients 
with low-flow, low-gradient aortic stenosis and reduced ejection 
fraction without flow (contractile) reserve, particularly when CT 
calcium scoring confirms severe aortic stenosis (Class IIa, Level 
C).
Choice of intervention in symptomatic severe 
aortic stenosis
Surgical aortic valve replacement (SAVR) is recommended (1,2) 
in patients at low surgical risk and no other risk factors (frailty, 
porcelain aorta, sequelae of chest radiation, older age, previous 
cardiac surgery, chest deformations, etc) (Class I, Level C). 
Transcatheter aortic valve implantation (TAVI) is recommended 
in patients who are not suitable for SAVR as assessed by the 
Heart Team (Class I, Level B). It offers a less invasive option 
for the treatment of severe AS, with evidence supporting TAVI 
compared with medical therapy in inoperable patients and supe-
rior with surgical aortic valve replacement (SAVR) in high-risk 
patients.
Balloon aortic valvotomy (BAV) may be considered as a bridge 
to SAVR or TAVI in haemodynamically unstable patients or in 
patients with symptomatic severe aortic stenosis who require 
urgent major non-cardiac surgery (Class IIb, Level C).
BAV may be considered as a diagnostic means in patients with 
severe aortic stenosis or other potential causes for symptoms (i.e. 
lung disease) and in patients with severe myocardial dysfunc-
tion, pre-renal insufficiency or other organ dysfunction that may 
be reversible with balloon aortic valvotomy when performed in 
centres that can escalate to TAVI (Class IIb, Level C).
Asymptopmatic severe aortic stenosis
SAVR is indicated1,2 in asymptomatic patients with severe aortic 
stenosis and systolic LV dysfunction (LVEF <50%) not due to 
another cause (Class I, Level C).
SAVR is indicated in asymptomatic patients with severe aortic 
stenosis and an abnormal exercise test showing symptoms on ex-
ercise clearly related to aortic stenosis (Class I, Level C). SAVR 
should be considered in asymptomatic patients with severe 
aortic stenosis and an abnormal exercise test showing a decrease 
in blood pressure below baseline (Class IIa, Level C).
SAVR should be considered in asymptomatic patients with 
normal ejection fraction and none of the above-mentioned ex-
ercise test abnormalities if the surgical risk is low and one of the 
following findings is present (Class IIa, Level C):
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    • Very severe aortic stenosis defined by a Vmax >5.5 m/s
   • Severe valve calcification and a rate of Vmax progression 
≥0.3 m/s/year
    • Markedly elevated BNP levels ( >threefold age- and sex-cor-
rected normal range) confirmed by repeated measurements 
without other explanations
   • Severe pulmonary hypertension (systolic pulmonary artery 
pressure at rest >60 mmHg confirmed by invasive measurement) 
without other explanation.
Other indications for intervention
SAVR is indicated 1,2 in patients with severe aortic stenosis un-
dergoing CABG or surgery of the ascending aorta or of another 
valve (Class I, Level C).
SAVR should be considered in patients with moderate aortic 
stenosis undergoing CABG or surgery of the ascending aorta or 
of another valve after Heart Team decision (Class IIa, Level C).
concluSion
Severe AS is the most common form of valve heart disease. 
AVR is primary recommended when the aortic valve is severely 
stenotic and the patient is symptomatic. Most asymptomatic 
patients with severe AS should be managed conservatively, with 
close monitoring to detect new onset of symptoms, except those 
with systolic LV dysfunction, an abnormal exercise test, very se-
vere aortic stenosis, severe valve calcification, markedly elevated 
cardiac biomarkers and severe pulmonary hypertension without 
other explanation. TAVI offers a less invasive option for the 
treatment of severe AS, with evidence supporting TAVI com-
pared with medical therapy in inoperable patients and superior 
with SAVR in high-risk patients. 
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